A detailed analysis of blood samples from Ebola patients in Sierra Leone is providing clues about the progression of the effects of the Ebola virus in patients and potential treatment pathways. The findings point to a critical role for a molecular pathway that relies on the common nutrient choline, as well as the importance of cellular bodies known as microvesicles.
Researchers amalgamated the expertise of two European Union expert networks: EMERGE (Efficient response to highly dangerous and emerging pathogens at EU level) and EVD-LabNet (Emerging Viral Diseases Laboratory Network), in order to select and analyze the relevant and some of controversial aspects of Crimean-Congo hemorrhagic fever (CCHF) disease diagnostics with implications for laboratory management of human CCHF cases and any exposed contacts.
Researchers showed that sofosbuvir, clinically approved against hepatitis C, inhibits yellow fever virus replication in liver cell lines and animal models. In vitro, sofosbuvir inhibits viral RNA replication, decreases the number of infected cells and the production of infectious virus particles.
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza.
Ebola could be transformed from a terrifying disease into something that can be managed at home if drug trials in the Democratic Republic of the Congo are successful, a leading scientist believes.
Researchers have discovered that certain derivatives of amodiaquine, a medication typically used to treat malaria, could provide a new therapeutic approach to treating patients infected with Ebola virus disease by blocking the viruses from entering cells.
Scientists have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. DMAbs may also provide a novel powerful platform for rapid screening of monoclonal antibodies enhancing preclinical development.
Health officials are preparing to launch a clinical trial designed to test whether experimental Ebola therapies improve patients’ chances of survival in the outbreak in the Democratic Republic of the Congo.
Researchers have identified a compound that strongly inhibits botulinum neurotoxin. That inhibiting compound, nitrophenyl psoralen, could be used as a treatment to reduce paralysis induced by botulism.
Georgia State scientists have identified a chemical compound that may work against the lethal Ebola virus.